The United States has pulled the plug on HIV funding for South Africa, a move that sends shockwaves through the Commonwealth's health security. For years, Washington has been the largest donor to the country's HIV/AIDS programmes, channelling billions through the President’s Emergency Plan for AIDS Relief (PEPFAR). Now, with a stroke of the pen, the tap has been turned off. The timing could not be worse: South Africa remains the epicentre of the global HIV epidemic, with over 8 million people living with the virus.
This is not merely a humanitarian setback. It is a fiscal and strategic miscalculation. Let us look at the numbers. PEPFAR has invested over $7 billion in South Africa since 2004. That money has kept millions on antiretroviral therapy, prevented mother-to-child transmission, and bolstered the country's healthcare infrastructure. The sudden cessation of these funds creates a funding gap that neither Pretoria nor international partners are prepared to fill. The South African government, already grappling with stagnant growth and a strained fiscus, cannot simply absorb this loss. The result will be a deterioration in treatment coverage, rising infection rates, and a potential resurgence of the epidemic.
The Commonwealth, which includes several high-burden HIV countries, should be alarmed. Health security is not a silo; it is a global public good. When one domino falls, others follow. The US decision undermines the collective resilience built over decades. It sends a signal that America's commitment to global health is conditional and fickle. For the Commonwealth, which relies heavily on US funding for health programmes across Africa and the Caribbean, this is a wake-up call. Diversifying funding sources and strengthening domestic health financing are no longer optional; they are existential.
Critics will argue that South Africa must take greater responsibility for its own health spending. They are not wrong. The country allocates roughly 4% of GDP to health, but inefficiencies and corruption plague the system. Yet, expecting a middle-income country to suddenly replace billions in donor funding is unrealistic. The market does not operate on goodwill; it operates on incentives. The US withdrawal creates a vacuum that China and other actors may be eager to fill, with geopolitical strings attached.
Central banks and finance ministries across the Commonwealth should take note. The HIV funding halt is not just a health issue; it is a macroeconomic risk. A sick population is a less productive population. Rising healthcare costs will strain government budgets, crowd out other investments, and potentially trigger capital flight as investor confidence wanes. The bond market will price in this risk. South African government bonds have already shown volatility. If the health crisis escalates, we could see a sovereign credit rating downgrade, further raising the cost of borrowing.
What can be done? In the short term, emergency bridging finance must be secured. The Global Fund and other multilateral mechanisms can provide some stopgap, but they cannot fully substitute for PEPFAR. The Commonwealth must convene an urgent summit to coordinate a response. In the medium term, South Africa and its partners must accelerate the transition to domestically financed health systems. This means cutting waste, improving tax collection, and creating an enabling environment for private sector investment in health.
The US has made its choice. It has decided that its domestic priorities outweigh its global responsibilities. That is a sovereign decision, but one with consequences. For the Commonwealth, the message is clear: no donor is permanent. The only sustainable health security is one you build yourself. The clock is ticking.
